Back to Journals » Infection and Drug Resistance » Volume 1

Micafungin in the treatment of invasive candidiasis and invasive aspergillosis

Authors Nathan P Wiederhold, Jason M Cota, Christopher R Frei

Published 12 January 2009 Volume 2008:1 Pages 63—77

DOI https://doi.org/10.2147/IDR.S3864

Review by Single-blind

Peer reviewer comments 4

Nathan P Wiederhold1, Jason M Cota2, Christopher R Frei1

1University of Texas at Austin College of Pharmacy, Austin, Texas, USA; 2University of the Incarnate Word Feik School of Pharmacy, San Antonio, Texas, USA

Abstract: Micafungin is an echinocandin antifungal agent available for clinical use in Japan, Europe, and the United States. Through inhibition of β-1,3-glucan production, an essential component of the fungal cell wall, micafungin exhibits potent antifungal activity against key pathogenic fungi, including Candida and Aspergillus species, while contributing minimal toxicity to mammalian cells. This activity is maintained against polyene and azole-resistant isolates. Pharmacokinetic and pharmacodynamic studies have demonstrated linear kinetics both in adults and children with concentration-dependent activity observed both in vitro and in vivo. Dosage escalation studies have also demonstrated that doses much higher than those currently recommended may be administered without serious adverse effects. Clinically, micafungin has been shown to be efficacious for the treatment of invasive candidiasis and invasive aspergillosis. Furthermore, the clinical effectiveness of micafungin against these infections occurs without the drug interactions that occur with the azoles and the nephrotoxicity observed with amphotericin B formulations. This review will focus on the pharmacology, clinical microbiology, mechanisms of resistance, safety, and clinical efficacy of micafungin in the treatment of invasive candidiasis and invasive aspergillosis.

Keywords: micafungin, echinocandin, Candida, Aspergillus, invasive candidiasis, invasive aspergillosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Long-term catheterization: current approaches in the diagnosis and treatment of port-related infections

Bustos C, Aguinaga A, Carmona-Torre F, Del Pozo JL

Infection and Drug Resistance 2014, 7:25-35

Published Date: 18 February 2014

Impact of restriction of cefepime use on the antimicrobial susceptibility of Gram-negative bacilli related to healthcare-associated infections in an orthopedic hospital

Oliveira PR, Paula AP, Dal-Paz K, Felix CS, Rossi F, Silva JS, Lima ALM

Infection and Drug Resistance 2011, 4:149-154

Published Date: 4 August 2011

Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections

Tze Shien Lo, Stephanie M Borchardt, Justin M Welch, Melissa A Rohrich, Augusto M Alonto, Anne V Alonto

Infection and Drug Resistance 2009, 2:41-49

Published Date: 30 June 2009

Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus

William J Peppard, Anne Daniels, Lynne Fehrenbacher, Jamie Winner

Infection and Drug Resistance 2009, 2:27-40

Published Date: 8 June 2009

Procalcitonin implication in renal cell apoptosis induced by acute pyelonephritis in children

Hafid Belhadj-Tahar, Yvon Coulais, Mathieu Tafani, François Bouissou

Infection and Drug Resistance 2008, 1:17-20

Published Date: 12 August 2008